Bacitracin A
Based on 1 Customer Validation
Bacitracin A is an antibiotic with antibacterial activity against Gram-positive bacteria. Bacitracin A forms a ternary complex with divalent metal ions and C55-isopentenyl pyrophosphate, thereby inhibiting peptidoglycan biosynthesis and cell wall synthesis. Bacitracin A induces the formation of protoplasts and L-form bacteria, alters membrane permeability, regulates metal ion transport, inhibits in vitro enzyme biosynthesis, disrupts the cytoplasmic membrane and exerts bactericidal activity. Bacitracin A can be used in studies related to bacterial infections, fungal infections and amoebic infections.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 97.3%
- CAS 番号: 22601-59-8
- 分子式: C66H103N17O16S
- 分子量:1422.69
-
保管条件:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
生物活性
製品説明
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HepG2 | IC50 |
254.6 μM
Compound: BAC
|
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
|
[PMID: 25593095] |
体外実験
Bacitracin A exhibits cytotoxicity against human renal tubular epithelial HK-2 cells, with an IC50 of 4.22 μM after 48 h of in vitro incubation[2].
Bacitracin A forms stable Co2+ and Zn2+ complexes: the cobalt complex binds undecaprenyl pyrophosphate (with a binding constant of 1.05×106 M-1), while the zinc complex binds phosphate and pyrophosphate derivatives[3].
Bacitracin A binds to Micrococcus lysodeikticus cells with a Km value of 3.7 × 10-6 M, which is consistent with its interaction targeting C55-isoprenyl pyrophosphate[1].
Bacitracin A (20-200 μg/mL; 14 h) completely inhibits the growth of Escherichia coli SC 9251 when the outer membrane of the bacterium is disrupted by polymyxin-agarose[1].
Bacitracin A (4-8 μM; 2 h) kills Gram-positive bacteria Staphylococcus aureus ATCC 29213 (MBC 4 μM), Streptococcus pneumoniae ATCC 49619 (MBC 8 μM), and Trueperella pyogenes ATCC 19411 (MBC 8 μM)[2].
Bacitracin A (BA) (2-4 μM; 18-24 h) inhibits the growth of Gram-positive bacteria Staphylococcus aureus ATCC 29213 (MIC 2 μM), Streptococcus pneumoniae ATCC 49619 (MIC 4 μM), and Trueperella pyogenes ATCC 19411 (MIC 4 μM); it potently inhibits the growth of Micrococcus luteus ATCC 9341 (MIC 0.39 μg/mL), Staphylococcus aureus IFO 12732 (MIC 3.13 μg/mL), Bacillus cereus ATCC 11778 (MIC 6.25 μg/mL), and Micrococcus lysodeikticus (MIC 1×10-7 M)[2][3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
化学情報
-
CAS 番号 22601-59-8
-
性状 Solid
-
分子量 1422.69
-
分子式 C66H103N17O16S
-
Color White to off-white
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
純度とドキュメンテーション
-
データシート (263 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
取扱説明書 (2659 KB)
参考文献
[1].
Toscano W A Jr. Bacitracin. Pharmac. Ther, 1982, 16: 199-210.
[Content Brief]
[2]. Hong W, et al. Synthesis, construction, and evaluation of self-assembled nano-bacitracin A as an efficient antibacterial agent in vitro and in vivo. International journal of nanomedicine. 2017;12:4691-4708. [Content Brief]
[3]. Ming LJ, et al. Metal binding and structure-activity relationship of the metalloantibiotic peptide bacitracin. Journal of inorganic biochemistry. 2002 Jul 25;91(1):46-58. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)